Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18101049 | 0.76 | PDK2 (0.44) | PDK2MAPTHPGDTSHRALDH1A1 | |
| SCHEMBL18101050 | 0.76 | PDK2 (0.44) | PDK2MAPTHPGDTSHRALDH1A1 | |
| SCHEMBL1346099 | 0.74 | PDK2 (0.41) | PDK2MAPTHPGDTSHRALDH1A1 | |
| SCHEMBL10562946 | 0.72 | MAPT (0.46) | PDK2MAPTHPGDTSHRALDH1A1 | |
| SCHEMBL8850768 | 0.71 | PDK2 (0.42) | PDK2MAPTHPGDTSHRALDH1A1 | |
| SCHEMBL4008419 | 0.69 | ALDH1A1 (0.60) | MAPTHPGDALDH1A1GAAAKR1B1 | |
| SCHEMBL7513748 | 0.69 | MAPT (0.43) | PDK2MAPTHPGDTSHRALDH1A1 | |
| SCHEMBL4009695 | 0.68 | MAPT (0.43) | MAPTHPGDTSHRALDH1A1GAA | |
| SCHEMBL10562607 | 0.68 | MAPT (0.43) | MAPTHPGDTSHRALDH1A1GAA | |
| SCHEMBL9749936 | 0.68 | HRH1 (0.53) | AKR1B1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562030-B2 | Process for the synthesis of olopatadine | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-02-07 | — | — | US | disclosed |
| US-9562030-B2 | Process for the synthesis of olopatadine | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-02-07 | — | — | US | disclosed |
| US-20160280677-A1 | A PROCESS FOR THE SYNTHESIS OF OLOPATADINE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-09-29 | — | — | US | disclosed |
| US-20160280677-A1 | A PROCESS FOR THE SYNTHESIS OF OLOPATADINE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280677-A1 | A PROCESS FOR THE SYNTHESIS OF OLOPATADINE | QDPR, OPRK1, PNMT | PDK2 2994/4885MAPT 2461/4885HPGD 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.